Kolistimetatnatrium Xellia

Colistimethate Sodium, the active ingredient in Kolistimetatnatrium Xellia, is a Polymyxin antibiotic presented as an injectable solution for intravenous use. It treats severe infections caused by susceptible Gram‑negative bacteria, including Pseudomonas aeruginosa, in hospitalized patients.

GNH USA supplies Kolistimetatnatrium Xellia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Colistimethate Sodium is employed to manage severe infections caused by Gram‑negative bacteria, particularly when resistance limits other options.

- Ventilator‑associated pneumonia: provides bactericidal activity against resistant Pseudomonas aeruginosa and other Gram‑negative pathogens. - Bloodstream infections (bacteremia): eradicates susceptible Gram‑negative organisms circulating in the blood. - Complicated urinary tract infections: treats infections caused by multidrug‑resistant Gram‑negative bacteria.

Colistimethate Sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nephrotoxicity: elevated serum creatinine and reduced renal function. - Neurotoxicity: paresthesia, dizziness, or headache. - Gastrointestinal upset: nausea, vomiting, or abdominal pain.

Serious or Rare Side Effects: - Anaphylactic reaction: sudden onset of rash, bronchospasm, or hypotension. - Neuromuscular blockade: respiratory paralysis, especially with concomitant muscle relaxants. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hemolysis: sudden drop in hemoglobin levels. - Thrombocytopenia: marked reduction in platelet count.

When using Colistimethate Sodium, clinicians should observe several safety measures.

- Renal monitoring: assess serum creatinine and urine output regularly. - Neuromuscular disease caution: avoid in patients with myasthenia gravis or other neuromuscular disorders. - Concomitant nephrotoxic drugs: adjust dose or discontinue if possible. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Administration under supervision: ensure dosing is prescribed by a qualified healthcare professional. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Colistimethate Sodium can interact with several other medicines, requiring careful management.

Major Interactions (Avoid): - Aminoglycosides: additive nephrotoxicity and ototoxicity. - Loop diuretics: increased risk of renal impairment. - Non‑depolarizing muscle relaxants: enhanced neuromuscular blockade.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate renal dysfunction. - Vancomycin: combined nephrotoxic potential. - Carbapenems: possible antagonistic antibacterial effect.